RHYTHM PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

RYTM$113.95+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)



· · · Three months ended March 31,
· 2024 · 2023
Revenues:
Product revenue, net	$25,967	$11,469
Total revenues	25,967	11,469
Costs and expenses:
Cost of sales	2,807	1,421
Research and development	128,665	37,945
Selling, general, and administrative	34,382	24,634
Total costs and expenses	165,854	64,000
Loss from operations	(139,887)	(52,531)
Other (expense) income:
Other income (expense), net	524	(27)
Interest expense	(4,755)	(3,061)
Interest income	3,046	3,440
Total other (expense) income, net	(1,185)	352
Loss before income taxes	(141,072)	(52,179)
Provision for income taxes	300	—
Net loss	$(141,372)	$(52,179)
Net loss per share, basic and diluted	$(2.35)	$(0.92)
Weighted-average common shares outstanding, basic and diluted	60,143,558	56,708,975

Other comprehensive loss:
Net loss	$(141,372)	$(52,179)
Foreign currency translation adjustment	(71)	21
Unrealized gain (loss), net on marketable securities	(244)	65
Comprehensive loss	$(141,687)	$(52,093)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.